Reference : Le médicament du mois. L'association calcipotriol-dipropionate de bétamethasone (dovobet).
Scientific journals : Article
Human health sciences : Dermatology
http://hdl.handle.net/2268/9370
Le médicament du mois. L'association calcipotriol-dipropionate de bétamethasone (dovobet).
French
[en] The calcipotriol-betamethasone dipropionate association.
Henry, Frédérique mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
Flagothier, Caroline [Centre Hospitalier Universitaire de Liège - CHU > > Dermatologie >]
Delvoye, Pierre [Centre Hospitalier Régional de Huy > > > > Dermatologie > >]
Pierard, Claudine [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
Pierard, Gérald mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie >]
2005
Revue Médicale de Liège
60
11
893-5
Yes (verified by ORBi)
0370-629X
Belgium
[en] Administration, Topical ; Betamethasone/administration & dosage/analogs & derivatives/therapeutic use ; Calcitriol/administration & dosage/analogs & derivatives/therapeutic use ; Drug Therapy, Combination ; Humans ; Inflammation ; Psoriasis/drug therapy
[en] The topical treatment of psoriasis benefits from the alternate use of dermocorticosteroids and vitamin D3 analogues. A new galenic formulation allows to combine them in a single application. Dovobet (LEO Pharma) ointment is the association of calcipotriol 50 microg/g with betamethasone dipoprionate 0.5 mg/g. This formulation boosts the therapeutic activity of calcipotriol. It also decreases the irritative inflammatory reaction due to calcipotriol without increasing the atrophogenic risk of the dermocorticoid.
http://hdl.handle.net/2268/9370

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
CALCIPOTRIOL.pdfNo commentaryPublisher postprint541.88 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.